Pseudofolliculitis of the Beard Treatment & Management

  • Author: Thomas G Greidanus, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 17, 2012
 

Medical Care

  • Chemical depilatories work by breaking the disulfide bonds in hair, which results in the hair being broken off bluntly at the follicular opening.[5]
    • Barium sulfide powder depilatories of about 2% strength can be made into a paste with water and applied to the beard area. This paste is removed after 3-5 minutes.
    • Calcium thioglycolate preparations come as powder, lotions, creams, and pastes. The mercaptan odor is often masked with fragrance. In rare cases, this fragrance can cause an allergic reaction. Calcium thioglycolate preparations take longer to work and are left on 10-15 minutes; chemical burns result if left on too long.
    • Chemical depilatories should not be used every day because they cause skin irritation. Every second or third day is an acceptable regimen. Irritation can be countered by using hydrocortisone cream. A lower pH or concentration, or a different brand, may also prove less irritating. Several products are available; therefore, trying a different product is encouraged if one depilatory proves to be unacceptable.
  • Topically applied tretinoin (Retin-A) has shown promise for some patients. When used nightly, it alleviates hyperkeratosis. It may remove the thin covering of epidermis that the hair becomes embedded in upon emerging from the follicle.[6, 7]
  • Topical combination cream (tretinoin 0.05%, fluocinolone acetonide 0.01%, and hydroquinone 4%) (Triluma) has been shown to provide some benefit by targeting the hyperkeratosis (tretinoin), inflammation (fluocinolone), and postinflammatory hyperpigmentation (hydroquinone).[8]
  • Mild topical corticosteroid creams reduce inflammation of papular lesions.[6]
  • For severe cases of pseudofolliculitis barbae with pustules and abscess formation, topical and oral antibiotics may be indicated.[9, 10]
    • Topical antibiotics may successfully reduce skin bacteria and treat secondary infection. These topicals include erythromycin, clindamycin, and combination clindamycin/benzoyl peroxide (Benzaclin, Duac) and erythromycin/benzoyl peroxide (Benzamycin) agents. Applying one of these agents once or twice per day is effective. Benzoyl peroxide applied topically once a day is also effective in reducing bacterial populations. It should be used sparingly and may be irritating to sensitive skin. It is a good first-line topical agent for persons with oily skin. Benzamycin is a combination of erythromycin and benzoyl peroxide. A once daily application has the benefits of both agents.
    • If pustules or abscess formation is evident, an oral antibiotic is indicated. Tetracycline is a common choice for a systemic antibiotic. Similar to a standard acne regimen, a dose of 500 mg twice a day used initially for 1-3 months is often effective.
  • Topical eflornithine HCL 13.9% cream (Vaniqa) has been used for excessive facial hair and in patients with pseudofolliculitis barbae. It is also used as a combination with laser therapy for hirsute women and pseudofolliculitis barbae patients. It decreases the rate of hair growth. In addition, the treated hair may become finer and lighter.[11]
  • Dermoscopy has been used to demonstrate the pathophysiology and improve compliance.[12]
Next

Surgical Care

  • Newer hair removal lasers may have a role in the treatment of pseudofolliculitis barbae. The problem with most laser and high-intensity light source hair removal modalities is that the natural skin pigment may be damaged by the laser because melanin in the hair shaft is the target chromophore. Devices being studied at this time may avoid this depigmenting complication. Diode laser treatments have been proven safe and effective in patients with skin phototypes I-IV.[13, 14, 15, 16]
  • The use of long-pulsed Nd:Yag laser in the treatment of pseudofolliculitis barbae demonstrated a decrease in papule formation, miniaturization, and reduction of hair counts in skin types IV, V and VI.[17] Most subjects had a return of normal hair growth after 6 months; however, 2 of 10 individuals had areas of permanent hair loss after 12-month follow-up. Adverse effects of long-standing hypopigmentation in this study were isolated, signifying that this particular laser is an encouraging modality of therapy.[18]
Previous
Next

Diet

No dietary therapies for pseudofolliculitis barbae have proven effective, and no dietary triggers of the condition have been identified.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Thomas G Greidanus, MD  Chair, Department of Emergency Medicine, Parkview Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Beth Honl, MD  Dermatology Associates, PC; Private Practice

Beth Honl, MD is a member of the following medical societies: American Academy of Dermatology and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Leonard Sperling, MD  Chair, Professor, Department of Dermatology, Uniformed Services University of the Health Sciences

Leonard Sperling, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD  Assistant Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Crutchfield CE 3rd. The causes and treatment of pseudofolliculitis barbae. Cutis. Jun 1998;61(6):351-6. [Medline].

  2. Quarles FN, Brody H, Johnson BA, et al. Pseudofolliculitis barbae. Dermatol Ther. May-Jun 2007;20(3):133-6. [Medline].

  3. Kindred C, Oresajo CO, Yatskayer M, Halder RM. Comparative evaluation of men's depilatory composition versus razor in black men. Cutis. Aug 2011;88(2):98-103. [Medline].

  4. Garcia-Zuazaga J. Pseudofolliculitis barbae: review and update on new treatment modalities. Mil Med. Jul 2003;168(7):561-4. [Medline].

  5. Olsen EA. Methods of hair removal. J Am Acad Dermatol. Feb 1999;40(2 Pt 1):143-55; quiz 156-7. [Medline].

  6. Childs ND. Tretinoin, hydrocortisone cream controls PFB. Skin and Allergy News. 1999;30(5):20.

  7. Kligman AM, Mills OH Jr. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Dermatol. Apr 1973;107(4):551-2. [Medline].

  8. Taylor S. Open-Label Case Study on Triple-Combination Cream in Patients with Pseudofolliculitis Barbae. J Am Acad Dermatol. 2005;52:P169.

  9. Brown LA Jr. Pathogenesis and treatment of pseudofolliculitis barbae. Cutis. Oct 1983;32(4):373-5. [Medline].

  10. Leyden JJ. Topical treatment for the inflamed lesion in acne, rosacea, and pseudofolliculitis barbae. Cutis. Jun 2004;73(6 Suppl):4-5. [Medline].

  11. Callender V, Young CM. Combination Laser and Eflornithine HCL 13.9% Cream: A First-line Therapy for Fitzpatrick Type IV-VI Patients With Excessive Facial Hair. J Am Acad Dermatol. Mar 2005;52(3) suppl:P209.

  12. Chuh A, Zawar V. Epiluminescence dermatoscopy enhanced patient compliance and achieved treatment success in pseudofolliculitis barbae. Australas J Dermatol. Feb 2006;47(1):60-2. [Medline].

  13. Bridgeman-Shah S. The medical and surgical therapy of pseudofolliculitis barbae. Dermatol Ther. 2004;17(2):158-63. [Medline].

  14. Kauvar AN. Treatment of pseudofolliculitis with a pulsed infrared laser. Arch Dermatol. Nov 2000;136(11):1343-6. [Medline].

  15. Perry PK, Cook-Bolden FE, Rahman Z, Jones E, Taylor SC. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol. Feb 2002;46(2 Suppl Understanding):S113-9. [Medline].

  16. Robins P, Battle EF Jr, Alexis AF, Cook-Bolden F, Alqubaisy Y, McLeod MP, et al. Unique laser techniques in patients with skin of color. J Drugs Dermatol. Dec 1 2011;10(12):4-26. [Medline].

  17. Schulze R, Meehan KJ, Lopez A, et al. Low-fluence 1,064-nm laser hair reduction for pseudofolliculitis barbae in skin types IV, V, and VI. Dermatol Surg. Jan 2009;35(1):98-107. [Medline].

  18. Ross EV, Cooke LM, Timko AL, Overstreet KA, Graham BS, Barnette DJ. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. Aug 2002;47(2):263-70. [Medline].

  19. Alexander AM. Evaluation of a foil-guarded shaver in the management of pseudofolliculitis barbae. Cutis. May 1981;27(5):534-7, 540-2. [Medline].

  20. Alexander AM, Delph WI. Pseudofolliculitis barbae in the military. A medical, administrative and social problem. J Natl Med Assoc. Nov 1974;66(6):459-64, 479. [Medline].

  21. Brauner GJ, Flandermeyer KL. Pseudofolliculitis barbae. Medical consequences of interracial friction in the US Army. Cutis. Jan 1979;23(1):61-6. [Medline].

  22. Coquilla BH, Lewis CW. Management of pseudofolliculitis barbae. Mil Med. May 1995;160(5):263-9. [Medline].

  23. Galaznik JG. A Pseudofolliculitis Barbae clinic for the black male who has to shave. J Am Coll Health. Dec 1984;33(3):126-7. [Medline].

  24. Halder RM. Pseudofolliculitis barbae and related disorders. Dermatol Clin. Jul 1988;6(3):407-12. [Medline].

  25. Nidecke A. Saving face: help black men avoid pseudofollicultis barbae. Skin and Allergy News. 1998;29 (10):46.

  26. Scheinfeld NS. Pseudofolliculitis barbae. Skinmed. May-Jun 2004;3(3):165-6. [Medline].

Previous
Next
 
Pseudofolliculitis barbae on the neck of a black man.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.